The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Considerations when screening donors for CH mutations to assess the risk of donor-derived leukemia
Ibrahim Yakoub-Agha, MD, PhD, University of Lille, Lille, France, shares insights into variations in clonal hematopoiesis (CH) mutations and considerations when screening donors to predict the risk of donor-derived leukemia. Dr Yakoub-Agha notes that not all mutations carry the same level of risk and emphasizes the importance of considering the psychological impact on families when deciding whether to screen for genetic mutations. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
